Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation

Author： Ochiai Takumi   Nishimura Kazuhiko   Watanabe Tomoo   Kitajima Masayuki   Nakatani Akinori   Inou Takashi   Washio Marie   Sakuyama Naoki   Sato Tsuyoshi   Kishine Kenji   Ochi Takanori   Ookubo Satoshi   Futagawa Shunji   Orikasa Hideki   Mashiko Satomi   Nagaoka Isao  

Publisher： Spandidos Publications

ISSN： 1792-1074

Source： Oncology Letters, Vol.3, Iss.2, 2012-02, pp. : 269-272

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

By                                

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1053-1057

Science Publishers

Access to resources Recommend Favorite

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)

By Maindrault-Goebel F.   Louvet C.   Andre T.   Carola E.   Lotz J.P.   Molitor J.L.   Garcia M.L.   Gilles-Amar V.   Izrael V.   Krulik M.   de Gramont A.  

European Journal of Cancer, Vol. 35, Iss. 9, 1999-09 ,pp. : 1338-1342

Elsevier

Access to resources Recommend Favorite

Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer

By Lin Peng-Chan   Chen Wei-Shone   Chao Ta-Chung   Yang Shung-Haur   Tiu Chui-Mei   Liu Jin-Hwang  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 3, 2007-08 ,pp. : 351-356

Springer Publishing Company

Access to resources Recommend Favorite

Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer

By                  

Oncology Letters, Vol. 5, Iss. 4, 2013-01 ,pp. : 1295-1300

Spandidos Publications

Access to resources Recommend Favorite

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)

By Maindrault-Goebel F.   de Gramont A.   Louvet C.   Andre T.   Carola E.   Mabro M.   Artru P.   Gilles V.   Lotz J.P.   Izrael V.   Krulik M.   for the Oncology Multidisciplinary Research Group GERCOR  

European Journal of Cancer, Vol. 37, Iss. 8, 2001-05 ,pp. : 1000-1005

Elsevier

Access to resources Recommend Favorite